Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators..

Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2.

2.

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N.

J Clin Oncol. 2012 Sep 10;30(26):3242-9. doi: 10.1200/JCO.2011.39.2779.

3.

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.

4.

Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.

Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F.

Cancer. 2012 May 1;118(9):2385-93. doi: 10.1002/cncr.26555.

5.

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.

Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA.

Ann Oncol. 2013 Aug;24(8):1999-2004. doi: 10.1093/annonc/mdt131.

6.

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.

Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1229-40. doi: 10.1007/s00432-013-1436-y.

7.

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT.

Ann Oncol. 2014 Feb;25(2):384-91. doi: 10.1093/annonc/mdt525.

8.

Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.

Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD; ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators..

Radiology. 2016 Apr;279(1):44-55. doi: 10.1148/radiol.2015150013.

PMID:
26624971
9.

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70.

10.

Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.

Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM.

Cancer. 2010 Sep 1;116(17):4168-77. doi: 10.1002/cncr.25296.

11.

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.

Breast Cancer Res Treat. 2012 Feb;131(3):827-36. doi: 10.1007/s10549-011-1488-0.

PMID:
21472434
12.

Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.

Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez F, Gianni L, Baselga J.

Clin Cancer Res. 2014 Jan 15;20(2):511-21. doi: 10.1158/1078-0432.CCR-13-0239.

13.

Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients.

Zhang GC, Qian XK, Guo ZB, Ren CY, Yao M, Li XR, Wang K, Zu J, Liao N.

Med Oncol. 2012 Dec;29(5):3222-31. doi: 10.1007/s12032-012-0242-8.

PMID:
22547076
14.

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.

Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ.

Breast Cancer Res. 2011 Mar 2;13(2):R22. doi: 10.1186/bcr2834.

15.

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S.

J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595.

PMID:
22508812
16.

Grb14 as an independent good prognosis factor for breast cancer patients treated with neoadjuvant chemotherapy.

Huang O, Jiang M, Zhang X, Xie Z, Chen X, Wu J, Liu H, Shen K.

Jpn J Clin Oncol. 2013 Nov;43(11):1064-72. doi: 10.1093/jjco/hyt130.

PMID:
24031083
17.

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).

von Minckwitz G, Rezai M, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer JU, Costa SD, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Untch M.

Ann Oncol. 2014 Jan;25(1):81-9. doi: 10.1093/annonc/mdt410.

PMID:
24273046
18.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J.

Lancet Oncol. 2014 May;15(6):640-7. doi: 10.1016/S1470-2045(14)70080-4.

PMID:
24657003
19.

TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.

Hertel PB, Tu D, Ejlertsen B, Jensen MB, Balslev E, Jiang S, O'Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO.

Breast Cancer Res Treat. 2012 Feb;132(1):225-34. doi: 10.1007/s10549-011-1896-1.

PMID:
22160637
20.

Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.

Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS; I-SPY 1 TRIAL Investigators., Esserman L, Park JW, van 't Veer LJ.

Breast Cancer Res. 2015 May 29;17:73. doi: 10.1186/s13058-015-0582-3.

Items per page

Supplemental Content

Support Center